Gadoteridol

CHEMBL1200593 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
558.7 g/mol
LogP
Phase
4

This gadolinium-based MRI contrast agent uses a macrocyclic structure that tightly holds the gadolinium ion, reducing the risk of release into body tissues. It is used to enhance visualization of lesions and vascular structures during brain and body MRI scans.

Berat Molekul

558,7000 g/mol

TPSA

154,00 Ų

Area Terapeutik

Mekanisme Kerja

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]

InChI

InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3

Molecular Formula

C17H29GdN4O7

HBD / HBA

1 / 11

Ikatan yang Dapat Dirotasi

5

Atom Berat

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This gadolinium-based MRI contrast agent uses a macrocyclic structure that tightly holds the gadolinium ion, reducing the risk of release into body tissues. It is used to enhance visualization of lesions and vascular structures during brain and body MRI scans.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Gadoteridol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200593. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60714. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.